Status:
COMPLETED
Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems
Lead Sponsor:
Tri-Service General Hospital
Conditions:
Anxiety Disorders
Sleep Apnea
Eligibility:
All Genders
20-85 years
Brief Summary
Generalized anxiety disorder (GAD) and obstructive sleep apnea (OSA) are two common diseases and share similar symptoms such as anxiety, poor attention, and poor sleep quality. However, the evidence t...
Detailed Description
Background: The symptoms of a generalized anxiety disorder (GAD) included excessive anxiety, restlessness, fatigue, poor concentration, irritability, and poor sleep quality. GAD is frequently combined...
Eligibility Criteria
Inclusion
- Diagnosis as drug-naïve GAD with an unexpected diagnosis of OSA
- Go to bed between 8:30 pm to midnight
- Have a BMI between 18-34
- Agree to sign an informed consent and use wearable devices to detect sleep
Exclusion
- Pregnancy and pacemaker implantation
- Shift workers or travel to 3 different timelines 7 days before study entry day
- Diabetes, cancer, neuropathy, any cardiovascular diseases that affect HRV
- Alcohol, illegal drugs, tobacco use
- Currently use medications that affect the HRV (e.g., antipsychotics, anticholinergics, antidepressants, and anticonvulsants)
Key Trial Info
Start Date :
May 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT05300386
Start Date
May 30 2018
End Date
January 31 2022
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tri-Service General Hospital
Taipei, Neihu, Taiwan, 114